EU/3/15/1577:

Adenovirus associated viral vector serotype 5 containing the human RPE65 gene

Overview

On 11 November 2015, orphan designation (EU/3/15/1577) was granted by the European Commission to Athena Vision Ltd, United Kingdom, for adenovirus associated viral vector serotype 5 containing the human RPE65 gene for the treatment of Leber's congenital amaurosis.

In September 2016, Athena Vision Ltd changed name to MeiraGTx UK II Limited.

The sponsorship was transferred to MeiraGTx B.V., The Netherlands in May 2019.

The sponsor’s address was updated in July 2021.

Key facts

Active substance
Adenovirus associated viral vector serotype 5 containing the human RPE65 gene
Intented use
Treatment of Leber's congenital amaurosis
Date of designation
11/11/2015
Orphan designation status
Positive
EU designation number
EU/3/15/1577

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

MeiraGTx B.V.
Paalbergweg 2-4
Amsterdam 
1105 AG
Noord-Holland
Netherlands
tel: +31858000860
e-mail: Janneke.Meulenberg@meiragtx.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating